Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Urogenital Neoplasms 3Prostatic Neoplasms 3Prostatic Diseases 3Neoplasms by Site 3Neoplasms 3Male Urogenital Diseases 3Genital Neoplasms, Male 3Genital Diseases, Male 3Carcinoma 3Transitional Cell Cancer of Renal Pelvis and Ureter 1

Interventions

padeliporfin 3Mitomycin 2valrubicin 1temsirolimus 1pembrolizumab 1palladium-bacteriopheophorbide 1enfortumab vedotin 1abiraterone 1abemaciclib 1Tadalafil 1Standard of Care 1Radiation Dose Hypofractionation 1Prednisone 1Prednisolone 1Phosphodiesterase 5 Inhibitors 1Gemcitabine 1Fluorouracil 1Drug Therapy 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Urogenital Neoplasms × padeliporfin × Clear all
NCT04225299 2020-11-13

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

Steba Biotech S.A.

Phase 3 Withdrawn
Genitourinary

Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT01310894 2019-07-11

PCM301

Steba Biotech S.A.

Phase 3 Completed
413 enrolled
Genitourinary

Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT01875393 2016-04-19

PCM304

Steba Biotech S.A.

Phase 3 Completed
81 enrolled
Genitourinary

Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡